Ebos Group Ltd (ASX: EBO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Ebos Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $3.59 billion
P/E Ratio 16.00
Dividend Yield 5.04%
Shares Outstanding 207.01 million
Earnings per share 1.327
Dividend per share 0.86
Year To Date Return -24.28%
Earnings Yield 6.25%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Ebos Group Ltd (ASX: EBO)
    Latest News

    A group of people in a corporate setting do a collective high five.
    Healthcare Shares

    3 ASX 200 healthcare shares to buy with 35% to 103% upside ahead

    Are any of these ASX shares in your portfolio?

    Read more »

    Numerous Australian dollar notes laid out.
    Superannuation

    How much superannuation do I need to earn $90,000 per year in passive income?

    This level of passive income could replace an annual wage.

    Read more »

    Five healthcare workers standing together and smiling.
    ASX Share Market News

    ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

    Healthcare outperformed while the ASX 200 weakened as earnings season continued last week.

    Read more »

    A man points at a paper as he holds an alarm clock, indicating the ex-dividend date is approaching.
    Dividend Investing

    16 ASX 200 shares with ex-dividend dates next week

    Telstra, Santos, JB Hi-Fi, and IAG are among the ASX shares about to go ex-dividend.

    Read more »

    Five healthcare workers standing together and smiling.
    Healthcare Shares

    EBOS FY26 earnings: profit edges higher, dividend steady

    EBOS Group posts a rise in FY26 profit and revenue as it maintains its final dividend for shareholders.

    Read more »

    Man holding fifty Australian Dollar banknotes in his hands, symbolising dividends.
    Dividend Investing

    These ASX 200 shares could generate $10,000 per year in passive income

    These ASX shares let you earn a $10,000 annual passive income off as little as a $125,000 investment.

    Read more »

    Happy female accountant looking at her tablet.
    Value Investing

    Down 50% – Are these the best value ASX 200 shares right now?

    These shares could be too cheap to ignore.

    Read more »

    A woman in a red dress holding up a red graph.
    Broker Notes

    4 ASX shares Macquarie says could return more than 40%

    The broker has made some bold predictions.

    Read more »

    a pot of gold at the end of a rainbow
    Broker Notes

    Macquarie names 2 ASX shares that could jump more than 80%

    These companies have strong market positions.

    Read more »

    Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
    Dividend Investing

    These 3 ASX shares will deliver better than 5% dividend yields, Macquarie says

    Looking for a steady income stream? Look no further.

    Read more »

    Worried woman calculating domestic bills.
    Broker Notes

    Why did this broker just lower its outlook on this ASX 200 stock?

    Despite a lowered outlook, attractive upside remains.

    Read more »

    A man sits nervously at his computer with his mouth resting against his hands clasped in front of him as he stares at the screen of his computer on a home desk.
    Healthcare Shares

    EBOS Group trims FY26 earnings guidance as fuel costs bite

    EBOS Group trims FY26 earnings guidance as elevated fuel costs weigh on its healthcare distribution businesses.

    Read more »

    Frequently Asked Questions

    Yes, EBOS Group has historically paid two partially franked shareholder dividends a year.

    EBOS Group generally pays its shareholder dividends in March and September. 

    Yes, EBOS has a dividend reinvestment plan to allow shareholders to reinvest all or part of their dividends.

    EBOS Group Ltd listed on the ASX on 6 September 2013.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    27 Aug 2026 $0.0217 0.00% Supplemental 18 Sep 2026
    05 Mar 2026 $0.0251 0.00% Supplemental 27 Mar 2026
    04 Sep 2025 $0.6150 0.00% Final 24 Sep 2025
    27 Feb 2025 $0.0251 0.00% Supplemental 21 Mar 2025
    29 Aug 2024 $0.5043 0.00% Final 18 Sep 2024
    29 Feb 2024 $0.1510 0.00% Supplemental 22 Mar 2024
    07 Sep 2023 $0.0251 0.00% Supplemental 29 Sep 2023
    07 Sep 2023 $0.4705 0.00% Final 29 Sep 2023
    02 Mar 2023 $0.0234 0.00% Supplemental 17 Mar 2023
    02 Mar 2023 $0.4259 0.00% Interim 17 Mar 2023
    08 Sep 2022 $0.0216 0.00% Supplemental 30 Sep 2022
    08 Sep 2022 $0.3800 0.00% Final 30 Sep 2022
    03 Mar 2022 $0.0207 0.00% Supplemental 18 Mar 2022
    03 Mar 2022 $0.3917 0.00% Interim 18 Mar 2022
    09 Sep 2021 $0.0203 0.00% Supplemental 24 Sep 2021
    09 Sep 2021 $0.3953 0.00% Final 24 Sep 2021
    04 Mar 2021 $0.0188 0.00% Supplemental 18 Mar 2021
    04 Mar 2021 $0.3506 0.00% Interim 18 Mar 2021
    24 Sep 2020 $0.0176 0.00% Supplemental 09 Oct 2020
    24 Sep 2020 $0.3289 0.00% Final 09 Oct 2020
    12 Mar 2020 $0.0165 0.00% Supplemental 03 Apr 2020
    12 Mar 2020 $0.3232 0.00% Interim 03 Apr 2020
    26 Sep 2019 $0.0163 0.00% Supplemental 11 Oct 2019
    26 Sep 2019 $0.3076 0.00% Final 11 Oct 2019
    14 Mar 2019 $0.0152 0.00% Supplemental 05 Apr 2019
    14 Mar 2019 $0.2920 0.00% Interim 05 Apr 2019
    27 Sep 2018 $0.2871 0.00% Final 12 Oct 2018
    15 Mar 2018 $0.0146 0.00% Supplemental 06 Apr 2018
    15 Mar 2018 $0.2766 0.00% Interim 06 Apr 2018
    28 Sep 2017 $0.0146 0.00% Supplemental 13 Oct 2017
    28 Sep 2017 $0.2664 0.00% Final 13 Oct 2017
    16 Mar 2017 $0.2453 0.00% Interim 07 Apr 2017
    29 Sep 2016 $0.2697 0.00% Final 14 Oct 2016
    10 Mar 2016 $0.2075 0.00% Interim 01 Apr 2016
    30 Sep 2015 $0.2024 0.00% Final 16 Oct 2015
    11 Mar 2015 $0.1884 0.00% Interim 02 Apr 2015
    01 Oct 2014 $0.1650 0.00% Final 17 Oct 2014
    12 Mar 2014 $0.1776 0.00% Interim 04 Apr 2014
    06 Apr 2011 $0.1350 0.00% Interim 21 Apr 2011
    08 Sep 2010 $0.1750 0.00% Final 08 Oct 2010
    15 Mar 2010 $0.1350 0.00% Interim 13 Apr 2010
    07 Sep 2009 $0.1450 0.00% Final 02 Oct 2009
    23 Mar 2009 $0.1050 0.00% Interim 21 Apr 2009
    15 Sep 2008 $0.0238 0.00% Supplemental 10 Oct 2008
    15 Sep 2008 $0.1350 0.00% Final 10 Oct 2008
    14 Apr 2008 $0.0168 0.00% Supplemental 09 May 2008
    14 Apr 2008 $0.0950 0.00% Interim 09 May 2008
    23 Oct 2007 $0.0229 0.00% Supplemental 26 Oct 2007
    23 Oct 2007 $0.1300 0.00% Final 26 Oct 2007
    16 Apr 2007 $0.0168 0.00% Supplemental 20 Apr 2007
    16 Apr 2007 $0.0950 0.00% Interim 20 Apr 2007
    24 Oct 2006 $0.0229 0.00% Supplemental 27 Oct 2006
    24 Oct 2006 $0.1300 0.00% Final 27 Oct 2006
    03 Apr 2006 $0.0168 0.00% Supplemental 07 Apr 2006
    03 Apr 2006 $0.0950 0.00% Interim 07 Apr 2006
    03 Oct 2005 $0.0221 0.00% Supplemental 07 Oct 2005
    03 Oct 2005 $0.1250 0.00% Final 07 Oct 2005
    14 Mar 2005 $0.0159 0.00% Supplemental 18 Mar 2005
    14 Mar 2005 $0.0900 0.00% Interim 18 Mar 2005

    EBO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Ebos Group Ltd

    EBOS Group Ltd (ASX: EBO) is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.

    EBOS Group also operates an animal health product wholesale, manufacturing, and retail business, as well as providing third-party logistics services.

    The vast majority of the company's revenue derives from its services to community pharmacies and institutional healthcare providers, which accounts for about 80% of revenue. Its Australian operations similarly contribute around 80% of its total revenue.

     

    EBO Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    03 Nov 2026 $17.27 $0.23 1.35% 97,239 $17.50 $17.50 $16.89
    02 Nov 2026 $17.04 $0.43 2.59% 255,150 $16.75 $17.07 $16.49
    30 Oct 2026 $16.61 $0.52 3.23% 207,514 $16.21 $16.75 $16.10
    29 Oct 2026 $16.09 $-0.04 -0.25% 66,248 $16.25 $16.25 $15.92
    28 Oct 2026 $16.13 $-0.41 -2.48% 66,832 $16.67 $16.67 $16.12
    27 Oct 2026 $16.54 $-0.47 -2.76% 114,956 $16.90 $16.90 $16.47
    26 Oct 2026 $17.01 $0.26 1.55% 147,795 $16.90 $17.09 $16.72
    23 Oct 2026 $16.75 $-0.41 -2.39% 126,718 $17.64 $17.64 $16.69
    22 Oct 2026 $17.16 $0.08 0.47% 174,975 $17.11 $17.35 $16.97
    21 Oct 2026 $17.08 $0.82 5.04% 124,844 $16.56 $17.25 $16.56
    20 Oct 2026 $16.26 $0.02 0.12% 67,163 $16.01 $16.32 $16.01
    19 Oct 2026 $16.24 $-0.35 -2.11% 84,131 $16.50 $16.60 $16.13
    16 Oct 2026 $16.59 $0.15 0.91% 106,509 $16.44 $16.69 $16.39
    15 Oct 2026 $16.44 $0.53 3.33% 137,725 $16.20 $16.46 $15.84
    14 Oct 2026 $15.91 $0.02 0.13% 46,454 $15.82 $16.02 $15.82
    13 Oct 2026 $15.89 $-0.06 -0.38% 69,904 $16.10 $16.10 $15.69
    12 Oct 2026 $15.95 $0.65 4.25% 80,487 $15.49 $16.00 $15.49
    09 Oct 2026 $15.30 $0.08 0.53% 71,125 $15.22 $15.35 $15.16
    08 Oct 2026 $15.22 $0.02 0.13% 105,388 $15.20 $15.35 $15.08
    07 Oct 2026 $15.20 $-0.15 -0.98% 50,498 $15.50 $15.50 $15.20
    06 Oct 2026 $15.35 $0.39 2.61% 76,866 $14.98 $15.50 $14.98

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 Sep 2026 Stuart McLauchlan Issued 160 $3,275
    Dividend Reinvestment Plan (DRP). NZ$
    18 Sep 2026 Julie Tay Issued 85 $897
    Dividend Reinvestment Plan (DRP).
    18 Sep 2026 Coline McConville Issued 27 $448
    Dividend Reinvestment Plan (DRP).
    31 Aug 2026 Matthew Muscio Expiry 17,859 $310,925
    As advised by the company. 17,859 rights lapsed
    27 Mar 2026 Stuart McLauchlan Issued 134 $2,960
    Dividend Reinvestment Plan (DRP). NZ$
    27 Mar 2026 Julie Tay Issued 71 $825
    Dividend Reinvestment Plan (DRP).
    27 Mar 2026 Coline McConville Issued 22 $485
    Dividend Reinvestment Plan (DRP). NZ$
    27 Feb 2026 Stuart McLauchlan Buy 1,500 $36,054
    On-market trade. NZ$
    05 Dec 2025 Coline McConville Buy 1,000 $24,347
    On-market trade.
    27 Nov 2025 Julie Tay Buy 1,000 $28,000
    On-market trade. NZ$
    10 Nov 2025 Matthew Muscio Buy 3,800 $108,563
    On-market trade. NZ$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Elizabeth(Liz) Mary Coutts Non-Executive DirectorNon-Executive Chairman Nov 2013
    Ms Coutts is Chair of the Remuneration Committee and a member of the Audit and Risk Committee. She is Chair of Oceania Healthcare Limited and 2degrees Group Limited, and Director of EBOS Group subsidiaries in New Zealand. She is a former Chair of Skellerup Holdings Limited, Ports of Auckland Limited, Meritec Group, Industrial Research, Life Pharmacy Limited, former director of Air New Zealand Limited, the Health Funding Authority, Sanford Limited, the Yellow Group of Companies and Tennis Auckland Region Incorporated, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac) and Marsh New Zealand Advisory Board, former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand, a former president of the Institute of Directors Inc and former Chief Executive of the Caxton Group of Companies.
    Mr Mark Alan Bloom Non-Executive Director Sep 2022
    Mr Bloom is a member of the Audit and Risk Committee. He is a non-executive director of ASX listed Storage King and AGL Energy Limited and a director of JewishCare NSW. He is a former director of Pacific Smiles Group Limited and Abacus Property Group. Mark has over 35 years experience as a finance executive, including as Chief Financial Officer at ASX listed Scentre Group Limited from its formation in July 2014 through to his retirement in April 2019. Prior to this, he was the Deputy Group CFO of Westfield Group for 11 years. He has also held a number of senior finance roles, including being CFO and executive director for insurance and financial services companies Liberty Life, South Africa and Manulife Financial, Canada.
    Mr Stuart McLauchlan Non-Executive Director Jul 2019
    Mr McLauchlan is Chairman of the Audit and Risk Committee and a member of the Remuneration Committee. He is a Chartered Fellow of the Institute of Directors and a Past President. He is a senior partner of GS McLauchlan & Co, and a Fellow of the New Zealand Institute of Chartered Accountants. He is currently chairman of Scott Technology Ltd and ADInstruments Ltd, and a nonexecutive director of Southlink Health Education Trust, Argosy Property Ltd, Dunedin Casinos Ltd and Scenic Hotels Group. He is also a governor of the New Zealand Sports Hall of Fame. He was formerly a member of the Marsh New Zealand Advisory Board, and director of Ngai Tahu Tourism Ltd.
    Mr Matthew Peter Muscio Non-Executive Director Jan 2025
    Mr Muscio was previously a board member for the Medical Technology Association of Australia from 2017 to 2023 and currently serves as Chair of Pacific Health Group and as a non executive board member of Tetrous Inc, a regenerative medicine company. His career spans more than 25 years in the medical device industry with the last 15 years in medical technology distribution under both public and private ownership models.
    Dr Tracey Leigh Batten Non-Executive Director Jul 2021
    Ms Batten is a member of the Remuneration Committee. She is currently a non executive director of Medibank Private Limited and Nanosonics Limited, and from 1 July 2026 is an independent director of IHH Healthcare Berhad. She was previously Chair of the Accident Compensation Corporation, a non executive director of National Institute of Water and Atmospheric Research, Abano Healthcare Group Limited and various other healthcare related research institutes, charities and industry and government bodies. During her executive career she was Group CEO of Imperial College Healthcare NHS Trust in the United Kingdom, Group CEO of St Vincent s Health Australia, CEO of Eastern Health and CEO of Dental Health Services Victoria.
    Ms Julie Tay Non-Executive Director May 2023
    Ms Tay is currently a director of Sonova, a global hearing care solutions company, headquartered in Switzerland and listed on the Swiss stock exchange. She has over 30 years experience in international leadership roles across consumer healthcare, medical devices and digital healthcare. She was most recently Senior Vice President and Managing Director, Asia Pacific and member of the global Executive Management Committee for Align Technology. Prior to this time, she was regional head of Bayer Healthcare (Diabetes Care) in Asia Pacific and also previously held senior executive roles in Asia at Johnson Diversey and Johnson & Johnson. She has also completed the International Directors Program at INSEAD, and is a member of the Young President's Organization (YPO).
    Ms Coline McConville Non-Executive Director Feb 2025
    Ms McConville brings to EBOS 20 years of governance experience advising a range of organisations operating in different countries and industries. Her expertise includes advising across acquisitive portfolio companies, complex distribution organisations, capital intensive businesses, consumer driven vertically integrated and global service companies. During her executive career, she was Chief Executive Officer and Chief Operating Officer for Clear Channel Communications (now iHeartMedia Inc.) and a management consultant with McKinsey and Co and LEK Consulting. She is currently a director of 3i Group (private equity) and was a member of the Supervisory Board of German based Tui AG (tourism and travel) until February 2026. Her previous directorships include Kings Cross Central General Partnership, TUI Travel, UTV Media, Travis Perkins, Fevertree Drinks, Inchcape, Wembley National Stadium, Shed Media, Halifax and HBOS.
    Grant Viney CEO Animal Care
    -
    Kristine James CEO Medical Technology
    -
    Nick Munroe CEO Retail Pharmacy Brands
    -
    Brett Barons CEO Symbion & Healthcare Distribution
    -
    Adam Hall Chief Executive Officer
    -
    Alistair Gray Chief Financial Officer
    -
    Mithran Naiker Chief Information Officer
    -
    Jacinta McCarthy Executive General Manager
    -
    Janelle Cain General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    BNP Paribas Nominees (NZ) Limited NZCSD 22,368,532 10.81%
    JP Morgan Nominees Australia Limited 15,940,350 7.70%
    Custodial Services Limited 15,325,872 7.41%
    HSBC Nominees (New Zealand) Limited NZCSD 14,447,604 6.98%
    Accident Compensation Corporation NZCSD 11,057,913 5.34%
    Forsyth Barr Custodians Limited 10,902,317 5.27%
    Sybos Holdings Pte Limited 9,957,825 4.81%
    Apex Custodian Nominees (NZ) Limited NZCSD 8,994,618 4.35%
    Citibank Nominees (New Zealand) Limited NZCSD 7,822,492 3.78%
    HSBC Nominees A/C NZ Superannuation Fund Nominees Limited NZCSD 7,788,795 3.76%
    HSBC Nominees (New Zealand) Limited A/C State Street NZCSD 7,227,463 3.49%
    JPMorgan Chase Bank NA NZ Branch Segregated Clients Acct NZCSD 7,193,425 3.48%
    HSBC Custody Nominees (Australia) Limited 4,805,567 2.32%
    FNZ Custodians Limited 4,613,901 2.23%
    JBWere (NZ) Nominees Limited 3,366,313 1.63%
    New Zealand Depository Nominee Limited 3,353,232 1.62%
    Citicorp Nominees Pty Limited 2,584,580 1.25%
    Generate Kiwisaver Public Trust Nominees Limited NZCSD 2,461,561 1.19%
    Simplicity Nominees Limited NNZCSD 2,387,814 1.15%
    PT (Booster Investments) Nominees Limited 1,928,218 0.93%

    Profile

    since

    Note